Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Cash from Financing Activities (2022 - 2026)

HeartSciences filings provide 5 years of Cash from Financing Activities readings, the most recent being $2.9 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 1529.6% to $2.9 million in Q1 2026 year-over-year; TTM through Jan 2026 was $8.2 million, a 172.14% increase, with the full-year FY2025 number at $2.7 million, down 73.57% from a year prior.
  • Cash from Financing Activities hit $2.9 million in Q1 2026 for HeartSciences, up from $1.5 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $9.1 million in Q1 2024 to a low of -$121522.0 in Q1 2023.
  • Median Cash from Financing Activities over the past 5 years was $782374.0 (2022), compared with a mean of $1.8 million.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 106.32% in 2023 and later soared 7610.17% in 2024.
  • HeartSciences' Cash from Financing Activities stood at -$116392.0 in 2022, then skyrocketed by 542.15% to $514629.0 in 2023, then skyrocketed by 269.53% to $1.9 million in 2024, then decreased by 20.66% to $1.5 million in 2025, then skyrocketed by 94.6% to $2.9 million in 2026.
  • The last three reported values for Cash from Financing Activities were $2.9 million (Q1 2026), $1.5 million (Q4 2025), and $3.6 million (Q3 2025) per Business Quant data.